Treatment Science · K-ATP channel opener · No human hair trial
Diazoxide
minoxidil's forgotten twin
Diazoxide is a blood-pressure and low-blood-sugar drug that opens the same class of ATP-sensitive potassium channel minoxidil opens, and its most common side effect is excess hair growth. It grew hair in cultured follicles and in all five balding monkeys in a 16-month study, yet it was never tested for pattern hair loss in a single human trial. Diazoxide is best understood as proof that the target is real, not as a treatment you can use.
- Hair growth is its most common side effect: in a pooled analysis of 1,142 hyperinsulinism patients, hypertrichosis was the single most common adverse effect, reported in about 45%, close to a coin flip (Yang 2021).
- It passed the same primate model as minoxidil and finasteride: topical diazoxide grew and maintained frontal hair in all five balding macaques over 16 months, without moving testosterone, blood sugar, insulin, or blood pressure (Uno 1990).
- The target is confirmed from the opposite direction: Cantu syndrome, where the channel is stuck partly open from birth, causes congenital hypertrichosis: living human proof that opening the channel grows hair (Grange 2020).
Evidence synthesis · K-ATP-opener pharmacology, isolated-follicle and primate data, and the human genetics of Cantu syndrome · Last reviewed July 2026
Overview
The blockbuster's twin that never got a bottle
Minoxidil is the blood-pressure drug that became a blockbuster hair treatment. What almost no one knows is that it has a twin, a second medicine from the same era that grows hair just as reliably in nearly every model it has been tested in, and yet never made it into a single bottle for your scalp.
Diazoxide was never developed, approved, or marketed to grow hair. It is a decades-old medicine used to treat dangerously high blood pressure and, more durably, hyperinsulinism, a condition where the pancreas releases too much insulin and blood sugar crashes. It grows hair anyway, reliably enough that doctors treat it as an expected complication rather than a surprise.
The K-ATP connection
Why diazoxide grows hair: two gates, not one
Diazoxide and minoxidil belong to the same drug family, the ATP-sensitive potassium channel openers. A K-ATP channel is a tiny gate on the surface of a cell, assembled from a regulatory sulfonylurea receptor (SUR) and a pore-forming subunit (Kir6). When these openers bind, they hold the gate open, letting potassium flow and changing how the cell behaves (Davies 2005).
Here is the detail most people miss. The human scalp follicle does not carry one of these gates. It carries two. Researchers found Kir6.2/SUR1 channels in the follicle's growing matrix and Kir6.1/SUR2B channels in the dermal papilla and sheath, and, importantly, minoxidil only activates the SUR2 form, not the SUR1 form (Shorter 2008). In the same human-follicle experiments, minoxidil and the channel blocker tolbutamide directly opposed each other, which is about as clean as it gets for showing the channel is doing the work.
That two-gate picture is why diazoxide is interesting rather than redundant. Minoxidil reaches for one of the follicle's potassium gates. Diazoxide, whose best-characterized target is the SUR1 form, can reach for the other. Two different keys, aimed at the same follicle, arriving at the same result: more hair.
Preclinical evidence
It grew hair in a dish, in isolated follicles, and in monkeys
The laboratory evidence for diazoxide is surprisingly deep for a drug nobody markets for hair. It stacks up across three levels. In cultured whole follicles, minoxidil, pinacidil, diazoxide, and cromakalim all stimulated DNA synthesis, the molecular signature of cells getting ready to divide, and the authors concluded the openers act on the follicle directly rather than through the bloodstream (Buhl 1993). In a cleaner isolated deer-follicle assay, diazoxide increased growth at 10 micromolar, and a sulfonylurea that shuts the channel abolished the effect, the fingerprint that the growth runs through the gate (Davies 2005).
The most striking result is also the oldest. In 1990, Hideo Uno, whose stumptailed-macaque model helped validate both minoxidil and finasteride, applied 5% topical diazoxide to the bald frontal scalps of balding macaques. All five treated animals showed thickening and maintenance of frontal hair for the entire 16-month period, with follicles enlarging and shifting from rest into the growth phase, and no change in testosterone, blood sugar, insulin, or blood pressure (Uno 1990). The hair effect was local, in the same primate model that gave minoxidil and finasteride their preclinical credibility.
The tell nobody followed up on
Topical diazoxide grew hair in all five balding monkeys in the gold-standard primate model in 1990, and still no one ever ran a human hair trial (Uno 1990).
Sometimes a drug's fate is decided by who bothers to develop it, not by what the biology can do.
The genetic proof
Cantu syndrome: the channel, confirmed from birth
The strongest proof that opening this channel grows hair is genetic, and nature ran the experiment for us. Cantu syndrome is a rare inherited condition caused by gain-of-function mutations in the genes that build the K-ATP channel, ABCC9 (SUR2) and KCNJ8 (Kir6.1). These mutations make the channel harder to switch off, so it stays open more than it should (Grange 2020).
One of the defining features of Cantu syndrome is congenital hypertrichosis. These children are born covered in hair. The gate that minoxidil and diazoxide pry open with a drug, Cantu patients have partly open from birth, in every cell, for life, and the hair follows. It is the living human proof that the channel is not a bystander. Opening it grows hair.
Why only one became a hair drug
Diazoxide did not fail. Nobody ever tried.
If diazoxide grew hair in a dish, in isolated follicles, in balding monkeys, and human genetics confirm the target, the obvious question is why it is not sitting next to minoxidil on the pharmacy shelf. The answer is not that it failed. It is that nobody ever ran the trial. A search of clinical-trial registries returns zero studies of diazoxide for hair or alopecia. Its entire human hair record is accidental, hypertrichosis observed while treating other diseases.
There are honest pharmacological reasons minoxidil pulled ahead. Diazoxide was slightly less potent than minoxidil in the head-to-head follicle assay (Davies 2005). Swallowed as a pill it carries dose-limiting side effects, and its most serious risk is pulmonary hypertension in newborns, serious enough that the FDA issued a formal warning in 2015 (Herrera 2018). And minoxidil had a well-tolerated topical formulation and a company willing to run the scalp trials. Diazoxide never got that champion.
| Effect | Approximate rate | Source |
|---|---|---|
| Hypertrichosis (excess hair) | about 45% | Yang 2021 |
| Fluid retention | about 20% | Yang 2021 |
| Edema | about 11% | Yang 2021 |
| Neutropenia | about 9% | Yang 2021 |
| Pulmonary hypertension (newborns) | about 2.4% | Herrera 2018 (FDA warning, 2015) |
These are the reasons chronic oral diazoxide is a hard sell for a cosmetic indication, and why any hair interest would center on a topical, not a pill.
The honest read
What diazoxide is, and what it is not
Diazoxide is not a hair-loss treatment. There is no human efficacy data for pattern baldness, no product, and no active development program for the scalp. Every human data point is a side effect, not an endpoint. The animal win is five monkeys in one lab in 1990, never replicated in people, and systemic diazoxide is genuinely rougher than minoxidil.
One more honest wrinkle: even minoxidil's mechanism is not fully settled. In cultured human outer-root-sheath cells, minoxidil sulfate did not open the identified potassium channels while the reference opener pinacidil did, which led some researchers to argue part of minoxidil's benefit may be vascular rather than a pure channel effect (Nakaya 1994). The K-ATP story is the leading explanation for both drugs, not a closed case.
What diazoxide is, is a proof of concept: one of several drugs that grow hair by opening the same class of channel, plus a genetic syndrome that confirms the target from the opposite direction. The lesson is not to take diazoxide. It is that the K-ATP channel is a real, druggable target for hair, and minoxidil is only the first key we happened to fit into it. The future of hair loss may not be a single lucky molecule. It may be the lock itself.
Frequently asked questions
Diazoxide, answered straight
Does diazoxide cause hair growth?
Yes. Excess hair growth (hypertrichosis) is diazoxide's most common side effect, reported in roughly 45% of hyperinsulinism patients in a pooled analysis of 1,142 people (Yang 2021). It happens because diazoxide opens the same class of ATP-sensitive potassium channel that minoxidil opens.
Is diazoxide the same as minoxidil?
No. They are different drugs with different primary uses: diazoxide for low blood sugar and high blood pressure, minoxidil for high blood pressure and hair loss. But both belong to the same pharmacological family of K-ATP channel openers, which is why both grow hair (Davies 2005).
Can you use diazoxide for hair loss?
There is no approved or studied use of diazoxide for pattern hair loss. It has never been tested in a human hair-loss trial, and oral diazoxide has significant side effects including fluid retention, high blood sugar, and, in newborns, a risk of pulmonary hypertension (Herrera 2018). Topical diazoxide grew hair in balding monkeys (Uno 1990) but has never been developed or proven for people. Anagen does not sell or compound diazoxide for hair loss.
Why does diazoxide grow hair but is not used like minoxidil?
Because no one ran the human trials. Minoxidil had a well-tolerated topical formulation and a company that developed it for hair; diazoxide never got that champion, despite a positive monkey study in 1990 (Uno 1990). It is a development gap, not a biology failure.
What is Cantu syndrome and how does it relate to hair?
Cantu syndrome is a rare genetic condition caused by mutations that leave the K-ATP channel stuck partly open. One of its hallmark features is being born with excess hair (congenital hypertrichosis), which is strong genetic evidence that opening this channel drives hair growth (Grange 2020).
Is topical diazoxide better than minoxidil for hair?
Unknown. No head-to-head human study exists. In one isolated-follicle lab assay, diazoxide was somewhat less potent than minoxidil (Davies 2005). Any claim that topical diazoxide beats minoxidil in people is unsupported by human evidence.
Limitations
What this page can and cannot support
The mechanism is well supported, but diazoxide has no human hair evidence at all. These constraints bound every claim above.
There is no human hair-loss trial of diazoxide. Every human data point is a side effect observed while treating other diseases, not an efficacy endpoint.
The animal win is small and old. Five monkeys, one lab, 1990, and never replicated in people (Uno 1990).
The preclinical record is not spotless. In one earlier assay diazoxide did not stimulate hair, which the authors attributed to poor solubility rather than biology (Buhl 1992).
Oral diazoxide is a rougher drug than minoxidil, with fluid retention, deliberate blood-sugar elevation, and a newborn pulmonary-hypertension warning (Herrera 2018).
Even minoxidil's mechanism is not fully settled. One study found minoxidil sulfate did not open the identified channels in a human cell model, suggesting a partly vascular contribution (Nakaya 1994).
Cantu syndrome confirms the target, not a treatment. It shows opening the channel grows hair; it does not show diazoxide is a safe or effective way to do that on the scalp.
Sources & citations
Every claim, traced to its source
The primary literature behind the mechanism, the isolated-follicle and primate data, and the genetics of Cantu syndrome above.
- 1Yang H, et al. Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: a systematic review and meta-analysis. PMID 33556119doi:10.1371/journal.pone.0246463
- 2Davies GC, Thornton MJ, Jenner TJ, et al. Novel and established potassium channel openers stimulate hair growth in vitro: implications for their modes of action in hair follicles. PMID 15816824doi:10.1111/j.0022-202X.2005.23643.x
- 3Buhl AE, Waldon DJ, Baker CA, Johnson GA Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. PMID 1545141doi:10.1111/1523-1747.ep12499788
- 4Buhl AE, Waldon DJ, Conrad SJ, et al. Potassium channel openers stimulate DNA synthesis in mouse epidermal keratinocyte and whole hair follicle cultures. PMID 7508914doi:10.1159/000211131
- 5Uno H, Kemnitz JW, Cappas A, Adachi K The effects of topical diazoxide on hair follicular growth and physiology of the stumptailed macaque. PMID 2085361doi:10.1016/0923-1811(90)90130-6
- 6Shorter K, Farjo NP, Picksley SM, et al. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. PMID 18258787doi:10.1096/fj.07-099424
- 7Grange DK, Nichols CG, Singh GK, et al. Cantu Syndrome. PMID 25275207
- 8Herrera A, Vajravelu ME, Givler S, et al. Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide. PMID 30247666doi:10.1210/jc.2018-01613
- 9Nakaya Y, Hamaoka H, Kato S, et al. Effect of minoxidil sulfate and pinacidil on single potassium channel current in cultured human outer root sheath cells. PMID 7947101doi:10.1016/0923-1811(94)90041-8
The K-ATP opener you can actually use
The channel opener with human hair data
Diazoxide is discussed here to illustrate the mechanism, not as a treatment. Minoxidil is the potassium-channel opener with published human hair results and a real formulation. It is used off-label for hair loss and is not FDA-approved for that use in oral form; a licensed clinician decides whether it is appropriate for you, and individual results vary.
